Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Irene Ferrer

Showing results (1-10 of 67) with videos related to

Pageof 7
Sort By:
Expert Opinion on Therapeutic Patents|June 1, 2019
A patent review of FGFR4 selective inhibition in cancer (2007-2018)Alvaro Quintanal-Villalonga, Irene Ferrer, Sonia Molina-Pinelo, et al.
Disease Markers|August 18, 2018
Corrigendum to "Tyrosine Kinase Receptor Landscape in Lung Cancer: Therapeutical Implications"A Quintanal-Villalonga, Luis Paz-Ares, Irene Ferrer, et al.
Disease Markers|August 17, 2016
Tyrosine Kinase Receptor Landscape in Lung Cancer: Therapeutical ImplicationsA Quintanal-Villalonga, Luis Paz-Ares, Irene Ferrer, et al.
Plants (Basel, Switzerland)|January 26, 2019
Autotoxicity of Diterpenes Present in Leaves of <i>Cistus ladanifer</i> LNatividad Chaves Lobón, Irene Ferrer de la Cruz, Juan Carlos Alías Gallego
Disease Markers|July 23, 2016
Proteomic-Based Approaches for the Study of Cytokines in Lung CancerÁngela Marrugal, Laura Ojeda, Luis Paz-Ares, et al.
Disease Markers|August 3, 2018
Corrigendum to "Proteomic-Based Approaches for the Study of Cytokines in Lung Cancer"Ángela Marrugal, Laura Ojeda, Luis Paz-Ares, et al.
Cell Cycle (Georgetown, Tex.)|June 15, 2011
Spinophilin loss contributes to tumorigenesis in vivoIrene Ferrer, Sandra Peregrino, Marta Cañamero, et al.
Human Pathology|July 13, 2013
Epithelial-to-mesenchymal transition and stem cells in endometrial cancerCristina Mirantes, Iñigo Espinosa, Irene Ferrer, et al.
Clinical Therapeutics|May 10, 2016
Current Challenges in Cancer TreatmentJon Zugazagoitia, Cristiano Guedes, Santiago Ponce, et al.
Lung Cancer (Amsterdam, Netherlands)|October 1, 2018
KRAS-Mutant non-small cell lung cancer: From biology to therapyIrene Ferrer, Jon Zugazagoitia, Stephan Herbertz, et al.
Pageof 7

Showing results (1-10 of 67) with videos related to

Sort By:
Pageof 7
Expert Opinion on Therapeutic Patents|June 1, 2019
A patent review of FGFR4 selective inhibition in cancer (2007-2018)Alvaro Quintanal-Villalonga, Irene Ferrer, Sonia Molina-Pinelo, et al.
Disease Markers|August 18, 2018
Corrigendum to "Tyrosine Kinase Receptor Landscape in Lung Cancer: Therapeutical Implications"A Quintanal-Villalonga, Luis Paz-Ares, Irene Ferrer, et al.
Disease Markers|August 17, 2016
Tyrosine Kinase Receptor Landscape in Lung Cancer: Therapeutical ImplicationsA Quintanal-Villalonga, Luis Paz-Ares, Irene Ferrer, et al.
Plants (Basel, Switzerland)|January 26, 2019
Autotoxicity of Diterpenes Present in Leaves of <i>Cistus ladanifer</i> LNatividad Chaves Lobón, Irene Ferrer de la Cruz, Juan Carlos Alías Gallego
Disease Markers|July 23, 2016
Proteomic-Based Approaches for the Study of Cytokines in Lung CancerÁngela Marrugal, Laura Ojeda, Luis Paz-Ares, et al.
Disease Markers|August 3, 2018
Corrigendum to "Proteomic-Based Approaches for the Study of Cytokines in Lung Cancer"Ángela Marrugal, Laura Ojeda, Luis Paz-Ares, et al.
Cell Cycle (Georgetown, Tex.)|June 15, 2011
Spinophilin loss contributes to tumorigenesis in vivoIrene Ferrer, Sandra Peregrino, Marta Cañamero, et al.
Human Pathology|July 13, 2013
Epithelial-to-mesenchymal transition and stem cells in endometrial cancerCristina Mirantes, Iñigo Espinosa, Irene Ferrer, et al.
Clinical Therapeutics|May 10, 2016
Current Challenges in Cancer TreatmentJon Zugazagoitia, Cristiano Guedes, Santiago Ponce, et al.
Lung Cancer (Amsterdam, Netherlands)|October 1, 2018
KRAS-Mutant non-small cell lung cancer: From biology to therapyIrene Ferrer, Jon Zugazagoitia, Stephan Herbertz, et al.
Pageof 7